{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T14:44:02Z","timestamp":1720622642147},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T00:00:00Z","timestamp":1537315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s40264-018-0723-6","type":"journal-article","created":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T04:45:13Z","timestamp":1537332313000},"page":"77-83","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Assessment of Self-Administration of Romiplostim in Patients with Immune Thrombocytopenic Purpura after Receipt of Home Administration Training Materials: a Cross-Sectional Study"],"prefix":"10.1007","volume":"42","author":[{"given":"Martin","family":"Schipperus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Kaiafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Wetten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Kreuzbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Boshier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anouchka","family":"Seesaghur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,19]]},"reference":[{"issue":"10","key":"723_CR1","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s12325-015-0251-z","volume":"32","author":"D Provan","year":"2015","unstructured":"Provan D, Newland AC. Current management of primary immune thrombocytopenia. Adv Ther. 2015;32(10):875\u201387.","journal-title":"Adv Ther."},{"issue":"6","key":"723_CR2","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1046\/j.1365-2141.2003.04547.x","volume":"122","author":"AJ Neylon","year":"2003","unstructured":"Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR, Northern Region Haematology Group. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol. 2003;122(6):966\u201374.","journal-title":"Br J Haematol"},{"issue":"22","key":"723_CR3","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1182\/blood-2014-05-578336","volume":"124","author":"G Moulis","year":"2014","unstructured":"Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood. 2014;124(22):3308\u201315.","journal-title":"Blood"},{"issue":"3","key":"723_CR4","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/blood.V94.3.909.415k02_909_913","volume":"94","author":"H Frederiksen","year":"1999","unstructured":"Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood. 1999;94(3):909\u201313.","journal-title":"Blood"},{"issue":"2","key":"723_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1600-0609.2009.01247.x","volume":"83","author":"PE Abrahamson","year":"2009","unstructured":"Abrahamson PE, Hall SA, Feudjo-Tepie M, Mitrani-Gold FS, Logie J. The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review. Eur J Haematol. 2009;83(2):83\u20139.","journal-title":"Eur J Haematol"},{"issue":"2","key":"723_CR6","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","volume":"115","author":"D Provan","year":"2010","unstructured":"Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168\u201386.","journal-title":"Blood"},{"key":"723_CR7","unstructured":"Nplate summary of product characteristics. 2016. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000942\/human_med_000938.jsp&mid=WC0b01ac058001d124 (cited 2018 Feb 12)."},{"issue":"3","key":"723_CR8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/bjh.12260","volume":"161","author":"DJ Kuter","year":"2013","unstructured":"Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013;161(3):411\u201323.","journal-title":"Br J Haematol"},{"key":"723_CR9","unstructured":"Guideline on good pharmacovigilance practices (GVP). Module XVI\u2014risk minimisation measures: selection of tools and effectiveness indicators (EMA\/204715\/2012 Rev 2). 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/02\/WC500162051.pdf (28 Mar 2017 [cited 2018 24 Jan])."},{"key":"723_CR10","unstructured":"Pharmacovigilance Risk Assessment Committee. Good practice guide on recording, coding, reporting and assessment of medication errors (EMA\/762563\/2014). 2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2015\/11\/WC500196979.pdf (cited 2018 24 Jan)."},{"key":"723_CR11","unstructured":"Pharmacovigilance Risk Assessment Committee. Good practice guide on risk minimisation and prevention of medication errors (EMA\/606103\/2014). 2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2015\/11\/WC500196981.pdf (cited 2018 24 Jan)."},{"issue":"8","key":"723_CR12","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/pds.3305","volume":"21","author":"L Prieto","year":"2012","unstructured":"Prieto L, Spooner A, Hidalgo-Simon A, Rubino A, Kurz X, Arlett P. Evaluation of the effectiveness of risk minimization measures. Pharmacoepidemiol Drug Saf. 2012;21(8):896\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"723_CR13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1080\/17425247.2018.1472572","volume":"15","author":"S Cohen","year":"2018","unstructured":"Cohen S, Klimiuk PA, Krahnke T, Assudani D. Successful administration of BI 695501, an adalimumab biosimilar, using an autoinjector (AI): results from a phase II open-label clinical study (VOLTAIRE((R))-RL). Expert Opin Drug Deliv. 2018;15(6):545\u20138.","journal-title":"Expert Opin Drug Deliv."},{"issue":"1","key":"723_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/00325481.2017.1251291","volume":"129","author":"DH Collier","year":"2017","unstructured":"Collier DH, Bitman B, Coles A, Liu L, Kumar S, Judd C. A novel electromechanical autoinjector, AutoTouch, for self-injection of etanercept: real-world use and benefits. Postgrad Med. 2017;129(1):118\u201325.","journal-title":"Postgrad Med"},{"key":"723_CR15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/1471-2377-11-126","volume":"11","author":"JT Phillips","year":"2011","unstructured":"Phillips JT, Fox E, Grainger W, Tuccillo D, Liu S, Deykin A. An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex(R) prefilled syringe in multiple sclerosis subjects. BMC Neurol. 2011;11:126.","journal-title":"BMC Neurol."},{"issue":"3","key":"723_CR16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2265.2007.03044.x","volume":"68","author":"JS Bevan","year":"2008","unstructured":"Bevan JS, Newell-Price J, Wass JA, Atkin SL, Bouloux PM, Chapman J, et al. Home administration of lanreotide autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxf). 2008;68(3):343\u20139.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"723_CR17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.contraception.2014.01.026","volume":"89","author":"A Beasley","year":"2014","unstructured":"Beasley A, White KO, Cremers S, Westhoff C. Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate. Contraception. 2014;89(5):352\u20136.","journal-title":"Contraception."},{"issue":"6","key":"723_CR18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40264-016-0410-4","volume":"39","author":"T Goedecke","year":"2016","unstructured":"Goedecke T, Ord K, Newbould V, Brosch S, Arlett P. Medication errors: new EU good practice guide on risk minimisation and error prevention. Drug Saf. 2016;39(6):491\u2013500.","journal-title":"Drug Saf"},{"issue":"5","key":"723_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.sapharm.2012.10.007","volume":"9","author":"MY Smith","year":"2013","unstructured":"Smith MY, Wallace LS. Reducing drug self-injection errors: a randomized trial comparing a \u201cstandard\u201d versus \u201cplain language\u201d version of patient instructions for use. Res Social Adm Pharm. 2013;9(5):621\u20135.","journal-title":"Res Social Adm Pharm"},{"issue":"3","key":"723_CR20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ajh.21616","volume":"85","author":"DR Terrell","year":"2010","unstructured":"Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol. 2010;85(3):174\u201380.","journal-title":"Am J Hematol"},{"key":"723_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1471-2288-7-30","volume":"7","author":"R McCarney","year":"2007","unstructured":"McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P. The Hawthorne effect: a randomised, controlled trial. BMC Med Res Methodol. 2007;7:30.","journal-title":"BMC Med Res Methodol"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-018-0723-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-018-0723-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-018-0723-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T13:42:30Z","timestamp":1720618950000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-018-0723-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,19]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["723"],"URL":"https:\/\/doi.org\/10.1007\/s40264-018-0723-6","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,19]]},"assertion":[{"value":"19 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Martin Schipperus and Georgia Kaiafa have no conflicts of interest to declare. Louise Taylor received funding for British Society for Haematology congresses in 2016 and 2017, and funding for the ITP Assembly in 2016 and 2017. Sally Wetten, Georg Kreuzbauer, Andy Boshier and Anouchka Seesaghur are employees of and hold stock in Amgen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was funded by Amgen (Europe) GmbH. Editorial assistance was funded by Amgen (Europe) GmbH and provided by Wanda Krall, Ph.D., of Wanda Krall Medical Communications.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The protocol, proposed informed consent form, and other written subject information were approved by the local investigational review board or ethics committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Patients\/caregivers provided written informed consent before participation in the study and in accordance with local laws and regulations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Consent"}}]}}